secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2026-08-14T12:40:50+00:00
Accession:  0001628280-26-056953
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen Q1 FY27 net loss $13.0M; cash $31.7M; FDA meeting planned for fasedienol path
--------------------------------------------------------------------------------

- Net loss $13.0M for Q1 ended June 30, 2026, vs $15.1M year-ago; revenue $1.2M from Fuji Pharma exclusivity expiration.
- Cash, equivalents and marketable securities $31.7M; sufficient into 2027 but not beyond one year from now.
- PALISADE-4 missed primary endpoint overall; post-hoc very severe SAD subpopulation showed nominally significant improvement vs placebo.
- FDA meeting planned this quarter to discuss potential Phase 3 registrational path for fasedienol in social anxiety disorder.
- Appointed Angel S. Angelov, M.D., MBA as CMO and Douglas J. Williamson, M.D. to Board; FDA 'Study May Proceed' for refisolone.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000162828026056953/0001628280-26-056953-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000162828026056953/vtgn-20260814.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-056953

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer